DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX tria…
Biotechnology
US, Minneapolis [HQ]
Revenue Breakdowns
Segment Analysis Beta
The financial segments are sourced from the SEC' 10-K statement.Revenue By Top Segments
DiaMedica Therapeutics Inc. can't present it's sankey chart.
Historical Revenue By Segment
Last 3Y, in million USDDiaMedica Therapeutics Inc. can't present revenue by segment
Get PRO Today
With PRO you can bypass the blur for the segment revenues of DiaMedica Therapeutics Inc..
If you want to see a demo, head over to the financial segments of AAPL